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OBJECTIVE—Insulin resistance is associated with the patho-
genesis of metabolic disorders as type 2 diabetes and obesity.
Given the emerging role of signal transduction in these syn-
dromes, we set out to explore the possible role that G protein–
coupled receptor kinase 2 (GRK2), ﬁrst identiﬁed as a G protein–
coupled receptor regulator, could have as a modulator of insulin
responses.
RESEARCH DESIGN AND METHODS—We analyzed the in-
ﬂuence of GRK2 levels in insulin signaling in myoblasts and
adipocytes with experimentally increased or silenced levels of
GRK2, as well as in GRK2 hemizygous animals expressing 50%
lower levels of this kinase in three different models of insulin
resistance: tumor necrosis factor- (TNF-) infusion, aging, and
high-fat diet (HFD). Glucose transport, whole-body glucose and
insulin tolerance, the activation status of insulin pathway com-
ponents, and the circulating levels of important mediators were
measured. The development of obesity and adipocyte size with
age and HFD was analyzed.
RESULTS—Altering GRK2 levels markedly modiﬁes insulin-
mediated signaling in cultured adipocytes and myocytes. GRK2
levels are increased by 2-fold in muscle and adipose tissue in
the animal models tested, as well as in lymphocytes from
metabolic syndrome patients. In contrast, hemizygous GRK2
mice show enhanced insulin sensitivity and do not develop
insulin resistance by TNF-, aging, or HFD. Furthermore, re-
duced GRK2 levels induce a lean phenotype and decrease
age-related adiposity.
CONCLUSIONS—Overall, our data identify GRK2 as an impor-
tant negative regulator of insulin effects, key to the etiopatho-
genesis of insulin resistance and obesity, which uncovers this
protein as a potential therapeutic target in the treatment of these
disorders. Diabetes 59:2407–2417, 2010
I
nsulin resistance, a diminished ability of cells to
respond to the action of insulin, is a key feature
associated with the pathogenesis of metabolic dis-
orders such as type 2 diabetes and obesity (1).
Alterations in any of the key components of the insulin-
signaling cascade, including negative regulators, have
been proposed to contribute to insulin resistance (1,2).
However, the origin and precise mechanisms mediating
insulin resistance in physiopathological conditions are not
fully understood (3).
Both aging and obesity are associated with increased
risk of developing type 2 diabetes and cardiovascular
disease. An increase in proinﬂammatory and a decrease in
anti-inﬂammatory factors is found in the obese state and
may inﬂuence glucose homeostasis and insulin sensitivity
(4,5). Peripheral tissues exposed to these proinﬂammatory
cytokines develop an insulin-resistant state (6). In fact,
obesity is now being considered a chronic state of low-
intensity inﬂammation. In this regard, the cytokine tumor
necrosis factor- (TNF-) is highly expressed in adipose
tissue of obese animals and humans, and obese mice
lacking either TNF- or its receptors show protection
against developing insulin resistance. The molecular
mechanisms underlying TNF-–mediated insulin resis-
tance have been studied in models of murine and human
myocytes and adipocytes and in vivo (7–11).
Insulin suppresses hepatic glucose production and reg-
ulates glucose uptake in muscle and fat through translo-
cation of GLUT4 to the cell surface (12,13). Insulin-
induced GLUT4 translocation requires at least two signals,
one mediated through phosphatidylinositol 3-kinase
(PI3K) and another via Gq/11 (14) in 3T3L1 adipocytes.
The activated insulin receptor can phosphorylate the G
protein subunit Gq/11, leading to activation of cdc42 and
PI3K, which triggers glucose transport stimulation (14–
16). Signaling of receptors via G proteins is regulated by G
protein–coupled receptor kinases (GRKs), a family of
seven serine/threonine protein kinases that speciﬁcally
recognize and phosphorylate agonist-activated G protein–
coupled receptors (GPCRs). This recruits arrestin proteins
that uncouple receptors from G proteins and promote
internalization. The ubiquitous GRK2 isoform has been
reported to regulate other pathways independently of its
GPCR phosphorylation ability (17,18). GRK2 can act as an
inhibitor of insulin-mediated glucose transport stimulation
in 3T3L1 adipocytes by interacting with Gq/11 function
independently of its kinase activity (19). GRK2 also inhib-
its basal and insulin-stimulated glycogen synthesis in
mouse liver FL83B cells (20). In this context, we have
investigated whether GRK2 may play a relevant physiolog-
ical role in the modulation of insulin responses in vivo.
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experimental models of insulin resistance, and a 50%
downregulation of GRK2 levels in hemizygous GRK2
/
mice is sufﬁcient to protect against TNF-, aging, or
high-fat diet (HFD)–induced alterations in glucose ho-
meostasis and insulin signaling, strongly arguing for a key
role for GRK2 in the modulation of insulin sensitivity in
physiological and pathological conditions.
RESEARCH DESIGN AND METHODS
Cell culture and transfections. The human liposarcoma cell line LiSa-2 (21)
was used as a cellular model of visceral human adipocytes and was main-
tained in Dulbecco‘s modiﬁed Eagle‘s medium (DMEM) supplemented with
10% fetal serum and antibiotics, at 37°C and 5% CO2. To induce insulin
resistance, human adipocytes were cultured for 21 days in serum-free
DMEM/F12 (1:1) as previously described (22). Peripheral blood mononuclear
cells, were isolated from blood samples with Lymphoprep (99% were
lymphocytes and monocytes) as previously described (23). The studies
involving samples from patients were carried out in accordance with the
Helsinki Declaration, and the protocol was approved by the Ethical Commit-
tee of the University Clinic of Navarra (supplementary information, available
in an online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/
db10-0771/DC1).
Mouse C2C12 myocytes (American Type Culture Collection) and immor-
talized murine white adipocytes were maintained in DMEM supplemented
with 10% fetal serum and antibiotics, at 37°C and 5% CO2. Cells were
transiently transfected according to the LipofectAMINE protocol (Invitrogen,
Paisley, U.K.), with 4 g of pcDNA3-GRK2-neo, pcDNA3-GRK2-K220R-hygro,
or ad-shGRK2-RNAi, to generate cell lines with increased or decreased GRK2
expression, respectively, or with empty vector (pcDNA3-hygro) as a control.
Metabolic assays. Glucose tolerance test (GTT) and insulin tolerance test
(ITT) were performed as we previously described (24). Glucose concentration
(mg/dl) was determined in tail blood samples using an automatic analyzer
(Accucheck from Roche). Other measurements were performed from blood
collected from the tail and centrifuged at 2,500g for 15 min to obtain the
serum. Insulin and leptin concentrations were assayed using a sensitive ELISA
kit (Linco Research, St. Louis, MO). Triglycerides released were assayed by an
enzymatic method using Free Glycerol Determination kit (Sigma-Aldrich, St.
Louis, MO).
Glucose uptake assay. Cells were stimulated for 30 min with insulin, and
glucose uptake was measured during the last 10 min of culture by incorpora-
tion of 2-deoxy-D[1–3H]-glucose as previously described (22,24). Individual
values were expressed as pmol of glucose per 10 min per mg of protein, and
results were expressed as percentage of stimulation over basal (control 
100).
In vivo signaling assay. Male mice (12- to 14-week-old) were subjected to
anesthesia (intraperitoneal injection of 60 mg/kg ketamine per 5 mg/kg
xylazine), and 25 mg epididymal adipose tissue was removed from each
mouse. Insulin (1 IU/kg body wt) was then injected via the cava vein, and a
similar amount of epididymal adipose tissue was removed, after 1, 3, and 7
min. Tissue samples were immediately frozen in liquid nitrogen and stored at
80°C. Epididymal adipose tissues were homogenized with a Polytron
homogenizer in lysis buffer and centrifuged at 100,000g for 15 min. The
supernatants were collected, assayed for protein concentration, and stored at
80°C until used. Other methods were performed as speciﬁed in the supple-
mentary information found in an online appendix.
RESULTS
Insulin signaling is regulated by GRK2 levels in adi-
pocytes and myocytes. To study the modulation of
insulin signaling by GRK2 in relevant insulin-targeted cell
types, we used murine white adipocytic and myocytic cell
lines expressing enhanced or decreased GRK2 protein
levels, or overexpressing a catalytically inactive mutant of
GRK2 (Fig. 1A). The increase in glucose uptake elicited by
insulin in both cell types was blocked in the presence of
enhanced GRK2 levels, whereas GRK2 knockdown led to a
slightly higher response (Fig. 1B). After acute insulin
challenge, IRS1 tyrosine phosphorylation and AKT activa-
tion were impaired upon GRK2 or GRK2-K220R overex-
pression, both in adipocytes and in myoblasts (Fig. 1C and
D), whereas reduced levels of GRK2 promoted the oppo-
site effect. Basal IRS1 protein levels were higher in cells
with silenced GRK2 and decreased in cells with elevated
GRK2, suggesting a functional relationship between GRK2
and IRS1 (Fig. 1C and D). Co-immunoprecipitation exper-
iments in adipocytes showed that both endogenous GRK2
and IRS1 proteins form a complex under basal conditions
that is completely disrupted after 10 min of insulin treat-
ment (Fig. 2A). GRK2 overexpression enhances the
amount of IRS1 associated to the kinase by 87% and
prevents the complete disruption of the complex by insu-
lin. In contrast, GRK2 downregulation decreases its basal
association with IRS1 and facilitates a complete disruption
of this complex by insulin.
Interestingly, a similar picture emerges when investigat-
ing such parameters in adipose tissue from wild-type (Wt)
or GRK2 hemizygous mice, expressing some 50% of GRK2
protein (25,26). The amount of basal IRS1/GRK2 com-
plexes also depends on GRK2 levels in vivo and insulin
infusion disrupts such complexes (Fig. 2B). Also, a faster
kinetics in insulin-mediated IRS1 and AKT phosphoryla-
tion (Fig. 2C) is observed in GRK2
/ mice.
Overall, our data indicate that GRK2 levels regulate
insulin signaling in skeletal muscle and adipose tissue both
in cultured cells and in vivo, most probably by mecha-
nisms independent of kinase activity and involving the
formation of dynamic GRK2/IRS1 complexes.
GRK2 protein expression is enhanced under insulin-
resistant conditions. If GRK2 is to play a role in the
modulation of insulin sensitivity in vivo, the expression of
this kinase should be altered in conditions characterized
by insulin resistance. Obesity-associated metabolic disor-
ders such as type 2 diabetes and insulin resistance can be
induced by TNF- infusion, aging, or HFD (1). Therefore,
we compared GRK2 expression in epididymal white adi-
pose tissue (eWAT), liver, and skeletal muscle obtained
from 3- and 9-month-old mice, as well as from mice fed on
a HFD or treated with TNF-, using only male mice (Fig.
3A and supplementary Table 1, available in an online
appendix). GRK2 expression levels were enhanced in
adipose tissue (from 1.3- to 1.9-fold) and muscle (1.4- to
1.7-fold) in every experimental condition studied, and
changes in liver expression were observed upon HFD
treatment. GRK2 expression was also enhanced by 2-
fold in eWAT tissue of the ob/ob model of obese mice (Fig.
3B) and by 2.5-fold in human adipocytes forced to develop
an insulin-resistant state upon a chronic challenge with
insulin (Fig. 3C). Finally, because lymphocyte GRK2 levels
have been reported to mirror changes in the kinase
expression in other organs under several physiopatholog-
ical circumstances (27), we analyzed the levels of GRK2 in
peripheral blood mononuclear cells obtained from pa-
tients with diverse degrees of insulin resistance (supple-
mentary Table 2, available in an online appendix). In these
cells, GRK2 levels were higher in insulin-resistant patients
compared with control individuals (Fig. 3D). Although
preliminary, our results indicate that GRK2 levels are
altered in murine experimental models and in human
samples under insulin-resistant conditions, suggesting that
this kinase might mediate the ability to induce insulin
resistance of different neurohumoral factors that are al-
tered in these situations (28,29).
GRK2
/ mice do not develop TNF-–induced insulin
resistance. To test the hypothesis that such moderate
changes in GRK2 expression levels may indeed alter
insulin signaling in vivo, we studied whole-body insulin
action and glucose homeostasis in age-matched wild-type
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/ male mice. These haploinsufﬁcient mice
constitute a good model to recapitulate differences in
GRK2 expression in the same range to those observed in
pathological conditions, as well as to evaluate the poten-
tial of therapeutic strategies aimed at decreasing GRK2
functionality in vivo. Whereas GRK2 knock-out mice die in
utero with a marked cardiac hypoplasia (30) and the
cardiac phenotype of GRK2
/ mice has been well char-
acterized (31,32), insulin signaling has not been investi-
gated so far in these animals.
Because TNF- infusion induces insulin resistance in
murine models in vivo (24,33), we examined insulin sen-
sitivity by GTTs and ITTs in wild-type and GRK2
/
3-month-old male mice after a 48-h treatment with TNF-
(Fig. 4A and C). In wild-type but not in GRK2
/ mice,
TNF- produced a signiﬁcant 29% increase in fasting blood
glucose levels (Table 1). Moreover, the additional pro-
nounced hyperglycemic effect of TNF- after glucose
injection observed in wild-type mice was attenuated in
GRK2
/ mice (Fig. 4A). The improved glucose tolerance
observed was not due to an increase in circulating insulin
because GRK2
/ mice had lower circulating insulin levels
than wild-type mice in both the fasted state (Table 1) and
during the GTT (Fig. 4B). These results suggest that the
more efﬁcient glucose clearance observed in GRK2
/
mice is caused by enhanced peripheral insulin sensitivity.
In line with this notion, the hypoglycemic effect of insulin
injection was impaired upon TNF- treatment in wild-type
animals but not in GRK2
/ mice (Fig. 4C).
Wild-type mice treated with TNF- showed a complete
impairment in insulin-induced AKT phosphorylation in
skeletal muscle, adipose tissue, and liver (Fig. 4D and
supplementary Fig. S2, available in an online appendix,
and supplementary Table 1) that was not detected in
GRK2
/ mice. Interestingly, TNF- substantially in-
creased GRK2 protein content in eWAT and muscle of
wild-type mice (by 82 and 42%, respectively) (Fig. 4D,
supplementary Fig. S2, and supplementary Table 1),
whereas the amount of GRK2 remained unaltered (in liver
and muscle) or below basal wild-type levels (adipose)
upon TNF- treatment in GRK2
/ mice (Fig. 4D, supple-
mentary Fig S2, and supplementary Table 1). Altogether,
these results suggest that GRK2 is a negative modulator of
insulin sensitivity and that lower GRK2 levels protect
against the systemic insulin resistance induced by TNF-.
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FIG. 1. Modulation on insulin sensitivity by GRK2. Immortalized murine white adipocytes and C2C12 myocytes were transiently transfected with empty
vector (control, C), pcDNA3-GRK2-neo (), the catalytically inactive pcDNA3-GRK2–K220R (K), or shGRK2-RNAi () to upregulate or knock-down
GRK2 expression, respectively. A: Lysates were analyzed by Western blot with the corresponding antibodies against GRK2 and -actin. For examples
of full-length blots, see supplementary Fig. S3, available in an online appendix. B: Adipocytes and myocytes were cultured for 24 h in serum-free and
low-glucose medium and stimulated in the absence or presence of 10 nmol/l insulin for 30 min. Glucose uptake was measured during the last 10 min by
incorporation of 2-deoxyglucose into the cells. Results were expressed as percentage of stimulation over basal of control cells (adipocytes, 5.3  0.3
pmol glucose/mg protein/10 min; myocytes, 45.8  3.2 pmol glucose/mg protein/10 min) and are means  SEM of ﬁve independent experiments. C:
Adipocytic and (D) myocytic cell lines were serum-starved overnight and then incubated in the absence or presence of 10 nmol/l insulin (Ins) for 10
min. Lysates were analyzed by Western blot with the corresponding antibodies against total and/or phosphorylated forms of IRS1 (Tyr 608), AKT
(Ser473), ERK1/2 (Thr202/Tyr204), GRK2, and -actin. Representative immunoblots of 4–6 independent experiments and densitometric analysis are
shown in (A, C, and D). *P < 0.01. For examples of full-length blots, see supplementary Fig. S3. Data in A, C, and D were normalized with the indicated
controls, and results are expressed as percent over basal (control cells transfected with empty vector).
L. GARCIA-GUERRA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2409GRK2 downregulation prevents the development of
aging-associated insulin resistance. In the model of
aging-associated insulin resistance, GRK2 downregulation
caused no differences in the GTTs or ITTs of young
(3-month-old) male mice (Fig. 5A–C), whereas in adult
9-month-old GRK2
/ male mice, glucose tolerance was
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tendency had already been observed at 5 months of age in
GRK2
/ mice (supplementary Fig. S1, available in an
online appendix). Aging also induced a 57% increase in
fasting glucose concentration in wild-type mice, limited to
29% in GRK2
/ mice (Table 1). Circulating levels of
insulin were higher in 9-month-old wild-type than in
GRK2
/ mice in response to an identical glucose load
(Fig. 5E). Consistently, GRK2
/ mice exhibited an en-
hanced decline in blood glucose levels upon administra-
tion of insulin (Fig. 5F) and lower fasting serum insulin
levels (Table 1). Altogether, these results suggest in-
creased whole-body insulin sensitivity in GRK2
/ mice, in
agreement with the values obtained for the homeostasis
model assessment index (Table 1).
Insulin-stimulated AKT phosphorylation was markedly
impaired with age in eWAT, liver, and muscle in wild-type
mice, while GRK2
/ animals maintained a robust activa-
tion of this pathway (Fig. 5G, supplementary Fig. S2, and
supplementary Table 1). Interestingly, in adult animals,
GRK2 protein expression was enhanced by 33 and 68% in
eWAT and muscle, respectively, compared with young
mice (Figs. 3A and 5G, supplementary Fig. S2, and supple-
mentary Table 1), while GRK2 levels in adult GRK2
/
mice were below the expression detected at 3 months of
age in wild-type animals in all tissues examined (Fig. 5G,
supplementary Fig. S2, and supplementary Table 1). Over-
all, these data suggest there is a threshold above which the
enhanced GRK2 expression observed with age markedly
affects insulin sensitivity in vivo.
GRK2
/ mice display protection against HFD-induced
insulin resistance and obesity. After a HFD regime for
12 weeks, wild-type mice gained signiﬁcantly more weight
than GRK2
/ mice (Fig. 6A). The overall increase in body
weight was 67% in wild-type and only 53% in GRK2
/
mice (Fig. 6B), without changes in food intake (Fig. 6C).
Consistently, even when adipocyte diameter was in-
creased in both groups, adiposity in GRK2 hemizygous
mice did not go beyond a certain threshold that was
exceeded only in wild-type mice, with the size of HFD-fed
GRK2
/ epididymal adipocytes being 45% inferior to that
of wild-type mice (Fig. 6D).
GTT analysis indicated a clear deterioration in glucose
metabolism in wild-type but not in HFD-fed GRK2
/
mice. In the HFD-fed state, GRK2
/ mice did not develop
glucose intolerance (Fig. 6E), because we detect no sta-
tistically signiﬁcant changes in glucose area between chow
diet (CD)-fed and HFD-fed GRK2
/ mice, which showed
lower blood glucose levels (Table 1) and an enhanced
reduction in blood glucose induced by insulin (Fig. 6F).
HFD caused a marked increase in circulating levels of
glucose, insulin, and triglycerides after 12 weeks of feed-
ing (Table 1) in wild-type mice, whereas these changes
were much more modest in GRK2
/ animals. These
parameters were not altered with CD in either type of
animal (data not shown). In summary, HFD promoted a
marked insulin-resistance state in wild-type mice, in ac-
cordance with the observed increase in homeostasis
model assessment values (Table 1), whereas insulin sen-
sitivity was preserved in GRK2
/ mice.
Insulin-induced AKT phosphorylation was dramatically
decreased in adipose tissue, liver, and muscle of wild-type
but not HFD-fed GRK2
/ mice (Fig. 6G, supplementary
Fig. S2, and supplementary Table 1). On the other hand, in
agreement with data in Fig. 3A, GRK2 protein levels were
signiﬁcantly increased in eWAT (84%), liver (26%), and
Wt GRK2+/-
B
*
A
* *
C  T N F α
C * *
D Adipose Liver Muscle
GRK2
Wt GRK2 +/-
Ins
TNFα
+
+
+
+
+
+
+
+
GRK2 +/- GRK2 +/-
β-actin
Wt Wt
P-AKT
AKT
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
00
Wt
GRK2 +/-
Wt
GRK2 +/-
C  T N F α
Wt
GRK2 +/-
Wt
GRK2 +/-
10
20
30
40
50
10
20
30
40
50
60
25
0
50
75
100
125
03 0 6 0
Time (min) Time (min)
90 120 0 30 60 90 120
Time (min)
04 5 30 15 60 75
100
200
300
400
500
600
B
l
o
o
d
 
g
l
u
c
o
s
e
 
(
m
g
/
d
l
)
B
l
o
o
d
 
i
n
s
u
l
i
n
 
(
m
g
/
d
l
)
B
l
o
o
d
 
g
l
u
c
o
s
e
 
(
%
)
G
l
u
c
o
s
e
 
a
r
e
a
 
(
m
g
/
d
l
•
m
i
n
•
1
0
3
)
G
l
u
c
o
s
e
 
a
r
e
a
 
(
m
g
/
d
l
•
m
i
n
•
1
0
2
)
I
n
s
u
l
i
n
 
a
r
e
a
 
(
n
g
/
m
l
•
m
i
n
)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0
10
20
30
40
50
60
0
FIG. 4. GRK2
/ mice do not develop TNF-–induced insulin resistance. Wt (open symbols, solid lines) and GRK2
/ (ﬁlled symbols, dotted lines)
adult male mice were treated with TNF- (0.1 g/g body wt, circles) or vehicle (100 l PBS plus 0.1% BSA, squares) for 48 h. A: GTTs were
performed on animals that had been fasted for 24 h and were given an injection of glucose (2 g/kg body wt). B: Circulating insulin levels during
the GTTs. C: ITTs were performed on fed male mice that had received insulin (0.8 IU/kg body wt). Glucose concentration was determined in blood
samples obtained from the tail vein. Results are means  SEM of eight animals for each group. Histograms on the right show the incremental area
under the curve. *P < 0.01. D: Wt and GRK2
/ male mice were treated or not with insulin (1 IU/kg body wt) for 15 min, and eWAT, liver, and
muscle were removed. Lysates were subjected to Western blot with the indicated antibodies against total and phosphorylated AKT (Ser473),
GRK2, and -actin. Representative immunoblots of four independent experiments are shown. See supplementary Fig. S2 and supplementary Table
1 for detailed quantiﬁcation of these data. For examples of full-length blots, see supplementary Fig. S4, available in an online appendix.
L. GARCIA-GUERRA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2411muscle (63%) of wild-type but not GRK2
/ mice fed on a
HFD (Fig. 6G, supplementary Fig. S2, and supplementary
Table 1). These results indicate that, even in different
cellular settings, whenever glucose intolerance develops,
GRK2
/ mice always maintain the levels of GRK2 protein
below those detected in wild-type and thus below a given
threshold that helps to prevent the development of insulin
insensitivity.
GRK2
/ mice exhibit reduced adiposity. In addition to
the data shown in Fig. 6A–C, a detailed weekly analysis of
the weight of wild-type and GRK2
/ animals from wean-
ing to 15 months of age (Fig. 7A) revealed less weight gain
for both male and female GRK2
/ mice (Fig. 7B), without
differences in daily food intake (Fig. 7C). Body weight
differences were detected as early as at 5 months of age
(Fig. 7A), and at 9 months of age, when some wild-type
mice are visibly obese (Fig. 7D), the average body weight
gain was 65 and 56% in male and female wild-type mice,
respectively, but only 56 and 43% in GRK2
/ mice (Fig.
7B). Body fat distribution was studied by magnetic nuclear
resonance imaging (MNRI) (Fig. 7E), showing that
9-month-old GRK2
/ mice had 33% less overall fat and
smaller fat depots than age-matched wild-type littermates
(Fig. 7F). Epididymal fat mass was reduced by 30% in
GRK2
/ compared with wild-type mice at 9 months of age
(Fig. 7G), and GRK2
/ mice exhibited reduced adipocytic
size in epididymal (threefold), retroperitoneal (4.6-fold),
and inguinal (threefold) fat (Fig. 7H). Interestingly, a
decrease in circulating leptin levels was also detected in
GRK2
/ animals at 9 months of age (Table 1). These
results indicate that downregulation of GRK2 is sufﬁcient
to induce a lean phenotype, which uncovers a previously
unidentiﬁed role for GRK2 in the regulation of adiposity.
DISCUSSION
In this report, we uncover GRK2 as a key modulator of
insulin sensitivity in vivo. In cultured adipocytes and
myoblasts, increased GRK2 or GRK2-K220R levels inhibit
insulin-stimulated glucose uptake and signaling in a ki-
nase-activity independent manner, by mechanisms involv-
ing the formation of dynamic GRK2/IRS1 complexes.
GRK2 expression is enhanced by 2-fold in insulin-resis-
tant human adipocytes, in blood mononuclear cells from
insulin-resistant patients, and in adipose and muscle tis-
sues in either TNF-–, aging-, or HFD-induced insulin-
resistance models. Importantly, GRK2
/ mice maintain
glucose tolerance and insulin signaling in the major insu-
lin-responsive tissues under such experimental conditions,
suggesting that enhanced GRK2 expression above a cer-
tain threshold markedly impairs insulin sensitivity in vivo.
Finally, we ﬁnd that GRK2 levels also regulate adiposity
during aging. Because GRK2 haploinsufﬁcient animals
show a phenotype quite similar to mice deﬁcient in other
well established negative regulators of insulin signaling
such as PTP1B (24,33,34), GRK2 can be regarded as a bona
ﬁde novel physiological regulator of insulin action and
leanness.
Previous reports have indicated that GRK2 could act as
an inhibitor of insulin action in cellular models. Binding of
GRK2 to Gq/11 impairs insulin-stimulated glucose uptake
in 3T3L1 preadipocytes (19), and enhanced GRK2 levels
favor insulin resistance induced by endothelin-1 in 3T3L1
cells (29) or by chronic -adrenergic receptor stimulation
in HEK-293 cells (28). GPCR agonists promote GRK2
interaction with Gq and also with IRS1, resulting in
T
A
B
L
E
1
.
M
e
t
a
b
o
l
i
c
p
a
r
a
m
e
t
e
r
s
o
f
W
t
a
n
d
G
R
K
2

/

m
a
l
e
m
i
c
e
P
a
r
a
m
e
t
e
r
3
m
o
n
t
h
s
9
m
o
n
t
h
s
H
F
D
T
N
F
-

W
t
G
R
K
2

/

W
t
G
R
K
2

/

W
t
G
R
K
2

/

W
t
G
R
K
2

/

B
l
o
o
d
g
l
u
c
o
s
e
(
m
g
/
d
l
)
F
e
d
1
5
5
.
4
	
5
.
9
1
5
2
	
6
.
3
1
7
0
.
2
	
6
.
7
§
1
5
2
.
7
	
6
.
4
*
1
8
4
.
4
	
9
.
7
§
1
6
8
	
5
.
7
*
§
1
4
8
	
6
.
5
1
3
5
	
7
.
1
F
a
s
t
e
d
8
1
.
6
	
3
.
6
8
1
.
6
	
2
.
6
1
2
8
.
3
	
6
.
0
§
1
0
5
.
6
	
8
.
3
*
§
1
1
0
	
3
.
7
§
8
9
.
6
	
4
.
0
*
§
1
0
5
.
8
	
6
.
2
§
8
3
	
2
.
3
*
S
e
r
u
m
i
n
s
u
l
i
n
(
n
g
/
m
l
)
F
e
d
0
.
6
5
	
0
.
0
8
0
.
4
9
	
0
.
0
9
0
.
9
8
	
0
.
0
5
§
0
.
6
0
	
0
.
0
2
*
2
.
5
0
	
0
.
3
0
§
1
.
0
3
	
0
.
0
1
*
§
–
–
F
a
s
t
e
d
0
.
1
3
	
0
.
0
2
0
.
1
3
	
0
.
0
1
0
.
6
1
	
0
.
0
5
§
0
.
4
4
	
0
.
0
4
*
§
0
.
5
4
	
0
.
0
2
§
0
.
1
6
	
0
.
0
1
*
§
0
.
2
6
	
0
.
0
2
§
0
.
1
5
	
0
.
0
2
*
T
r
i
g
l
y
c
e
r
i
d
e
s
(

g
/

l
)
F
e
d
0
.
0
4
6
	
0
.
0
0
2
0
.
0
5
4
	
0
.
0
0
1
*
0
.
0
3
8
	
0
.
0
0
5
§
0
.
0
4
7
	
0
.
0
0
6
§
0
.
1
4
0
	
0
.
0
2
0
§
0
.
0
6
4
	
0
.
0
0
1
*
§
–
–
F
a
s
t
e
d
0
.
0
1
8
	
0
.
0
0
2
0
.
0
1
1
	
0
.
0
0
1
*
0
.
0
3
5
	
0
.
0
0
1
§
0
.
0
3
3
	
0
.
0
0
2
§
0
.
0
6
0
	
0
.
0
0
2
§
0
.
0
4
5
	
0
.
0
0
7
*
§
–
–
L
e
p
t
i
n
(
n
g
/
m
l
)
F
e
d
6
.
7
	
1
.
5
6
.
6
	
1
.
3
8
.
4
	
1
.
7
6
.
1
	
1
.
7
1
4
	
3
.
6
§
1
3
.
1
	
3
.
0
§
–
–
H
O
M
A
0
.
6
3
	
0
.
0
7
0
.
6
2
	
0
.
0
8
5
.
0
2
	
0
.
6
3
§
2
.
5
3
	
0
.
1
6
*
§
3
.
5
2
	
0
.
4
2
§
0
.
8
5
	
0
,
0
7
*
1
.
6
3
	
0
.
0
9
§
0
.
7
4
	
0
.
0
6
*
D
a
t
a
a
r
e
m
e
a
n
s
	
S
E
M
o
f
m
e
a
s
u
r
e
m
e
n
t
s
o
b
t
a
i
n
e
d
f
o
r
8
–
1
8
a
n
i
m
a
l
s
f
o
r
e
a
c
h
g
r
o
u
p
.
*
W
t
v
s
.
G
R
K
2

/

;
P


0
.
0
5
.
§
3
m
o
n
t
h
s
v
s
.
9
m
o
n
t
h
s
,
f
e
d
a
H
F
D
o
r
t
r
e
a
t
e
d
w
i
t
h
T
N
F
-

;
P


0
.
0
5
.
S
e
r
u
m
f
r
o
m
W
t
a
n
d
G
R
K
2

/

3
-
a
n
d
9
-
m
o
n
t
h
-
o
l
d
m
a
l
e
m
i
c
e
,
f
e
d
o
n
a
H
F
D
f
o
r
1
2
w
e
e
k
s
,
o
r
a
d
u
l
t
m
a
l
e
m
i
c
e
t
r
e
a
t
e
d
w
i
t
h
T
N
F
-

a
s
i
n
F
i
g
.
4
w
a
s
c
o
l
l
e
c
t
e
d
,
a
n
d
t
h
e
i
n
d
i
c
a
t
e
d
m
e
t
a
b
o
l
i
c
p
a
r
a
m
e
t
e
r
s
w
e
r
e
m
e
a
s
u
r
e
d
a
s
d
e
t
a
i
l
e
d
i
n
R
E
S
E
A
R
C
H
D
E
S
I
G
N
A
N
D
M
E
T
H
O
D
S
.
T
h
e
h
o
m
e
o
s
t
a
s
i
s
m
o
d
e
l
a
s
s
e
s
s
m
e
n
t
(
H
O
M
A
)
i
n
d
e
x
w
a
s
c
a
l
c
u
l
a
t
e
d
a
s
t
h
e
p
r
o
d
u
c
t
o
f
t
h
e
f
a
s
t
i
n
g
p
l
a
s
m
a
i
n
s
u
l
i
n
l
e
v
e
l
(
m
U
/
m
l
)
a
n
d
t
h
e
f
a
s
t
i
n
g
p
l
a
s
m
a
g
l
u
c
o
s
e
l
e
v
e
l
(
m
m
o
l
/
l
)
,
d
i
v
i
d
e
d
b
y
2
2
.
5
.
CONTROL OF INSULIN RESISTANCE AND OBESITY BY GRK2
2412 DIABETES, VOL. 59, OCTOBER 2010 diabetes.diabetesjournals.orgdecreased insulin-stimulated glucose transport, IRS-serine
phosphorylation, and IRS1 degradation (29). Our data in
cultured cells as well as in adipose tissue in vivo show that
IRS1 levels as well as the amount of basal GRK2-IRS1
complexes depend on GRK2 expression and that insulin
stimulation rapidly disrupts basal IRS1/GRK2 complexes,
which is hampered in the presence of elevated levels of
GRK2. Overall, these data suggest that altered GRK2 levels
could lead to modulation of insulin signals through GRK2-
Gq/11 binding, GRK2-IRS1 association, and altered endo-
thelin-1 or -adrenergic-mediated transmodulation of the
insulin pathway. The precise contribution of such mecha-
nisms in different physiological conditions remains to be
investigated.
Interestingly, -arrestin2, another member of the GPCR
signal transduction pathway, positively regulates insulin
sensitivity by serving as a scaffold of AKT and Src to the
insulin receptor (35). -arrestin2 levels are downregulated
in liver and muscle in animal models and patients with
insulin resistance. Therefore, simultaneous upregulation
of GRK2 and downregulation of -arrestin2 in insulin-
resistant conditions could lead to major alterations in the
insulin signaling pathways and in GPCR–insulin receptor
cross-talk. It is worth noting that elevated levels of insulin
and IGF-1 have been shown to exert differential effects on
GRK2 and -arrestin2 expression (36,37). Enhanced GRK2
levels could alter the proposed novel insulin receptor–
arrestin signaling pathway by redirecting arrestin to other
interactors, such as GPCR, or, given the reported direct
interactions of the kinase with AKT or Src, by inhibiting
the formation of the arrestin/AKT/Src complexes.
GRK2 is degraded by the proteasome pathway by asso-
ciating with the Mdm2 E3-ubiquitin ligase, and activation
of the PI3K/AKT pathway by IGF-1 blocks Mdm2-mediated
GRK2 degradation, leading to enhanced GRK2 levels (38).
Consistently, chronic insulin has been recently shown to
increase GRK2 levels in HEK-293 and liver FL83B cells
(20,28), which is in agreement with the upregulation of
GRK2 we observe after insulin treatment in human adipo-
cytic cells. Thus, it is tempting to suggest that the hyper-
insulinemia associated with aging-, HFD-, or TNF-
–induced insulin-resistant conditions, and clinically
associated with obesity and type 2 diabetes, would trigger
the observed upregulation of GRK2 in such conditions.
Consistent with our ﬁndings, enhanced GRK2 expression
FIG. 5. GRK2 downregulation prevents the development of aging-associated insulin resistance. A: GTTs were performed on Wt (open circles, solid
lines) and GRK2
/ (ﬁlled circles, dotted lines) 3-month-old male mice as in Fig. 4A. B: Circulating insulin levels during the GTTs. C: ITTs were
performed on Wt (open circles) and GRK2
/ (ﬁlled circles) 3-month-old male mice as in Fig. 4C. D–F: GTTs and ITTs were performed as in
previous panels in Wt (open circles) and GRK2
/ (ﬁlled circles) 9-month-old male mice. *P < 0.01. G: Lysates from Wt and GRK2
/ 3- and
9-month-old male mice treated or not with insulin were processed as in Fig. 4D. Representative immunoblots of four independent experiments
are shown. See supplementary Fig. S2 and supplementary Table 1 for detailed quantiﬁcation of these data.
L. GARCIA-GUERRA AND ASSOCIATES
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model of insulin resistance and hyperinsulinemia (39).
An altered cytokine expression pattern typical of insu-
lin-resistant states could also contribute to enhance GRK2
expression levels. TNF- or IL-6 increase the expression of
other negative modulators of the insulin signaling cascade
like PTP1B (24,40), and we ﬁnd that TNF- also enhances
GRK2 protein content in adipose tissue and muscle of
wild-type mice in the presence of mild hyperinsulinemia.
As in GRK2
/ mice, PTP1B-deﬁcient animals also exhibit
protection against insulin resistance induced by TNF-
(24) or IL-6 (40). Proinﬂammatory mediators can modulate
endogenous GRK2 expression in a cell-type speciﬁc fash-
ion (41), and an increase in GRK2 protein is found upon
chronic IL-1 treatment (26,42). Interestingly, GRK2 ap-
pears to have a relevant role in the etiology and/or in the
development of several inﬂammatory diseases such as
multiple sclerosis and autoimmune arthritis (43). A role
for GRK2 in states of insulin resistance associated with
inﬂammatory diseases deserves further investigation.
The fact that the 50% downregulation of GRK2 levels is
sufﬁcient per se to protect against TNF--, aging-, or
HFD-induced alterations in glucose homeostasis and insu-
lin signaling strongly supports that this kinase is a key
modulator of insulin sensitivity in vivo and suggests new
therapeutic strategies against type 2 diabetes and obesity.
In fact, in animal models of type 2 diabetes, GRK2 inhibi-
tion through systemic delivery of small peptides derived
from its catalytic domain results in improved glucose
homeostasis (28,44). It remains to be established whether
inhibition of catalytic activity, downregulation of protein
expression, or targeted disruption of the speciﬁc interac-
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are the more appropriate strategies for speciﬁcally improv-
ing insulin sensitivity.
The GRK2
/ mice constitute a good model that reca-
pitulates a sustained systemic inhibition of kinase func-
tionality. We report here that GRK2 levels are important
modulators of age- and diet-induced adiposity. GRK2
/
mice gained less weight and showed diminished adipocyte
size with a HFD, and adult hemizygous animals displayed
reduced adiposity and lower circulating levels of insulin
and leptin. Aging is associated with fat mass accretion and
with decreased peripheral insulin sensitivity in humans
and rodents (45), and impaired insulin actions in adipose
tissue could represent a key step leading to the overall
insulin-resistance characteristic of adult and/or obese an-
imals (46). Adipocyte-conditioned medium impairs insulin
signaling in muscle cells (22) and hepatocytes (47), and
mice that exhibit reduced adiposity typically display im-
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FIG. 7. GRK2
/ mice exhibit reduced adiposity. A: Body weight evolution in male or female Wt (open circles, solid lines) and GRK2
/ (ﬁlled
circles, dotted lines) mice between 2 and 15 months of age. B: Percentage of change in body weight during 13 months. C: Daily food intake in 3-
and 9-month-old male Wt and GRK2
/ mice. D: Representative photograph showing 9-month-old Wt or GRK2
/ male mice. E: Adiposity in
9-month-old male mice measured by MNRI; white represents areas with >50% fat. F: Quantiﬁcation of several MNRI measurements. Results were
expressed as proportion between fat volumes vs. total mouse volume (fat vol/total vol). G: eWAT weight in 3- and 9-month-old male Wt and
GRK2
/ mice. H: Parafﬁn-embedded sections of WAT: retroperitoneal, epididymal, and inguinal fat pads from 9-month-old male Wt and GRK2
/
mice stained with hematoxylin and eosin. (Magniﬁcation 10; scale bar 50 m for all pictures.) Relative adipocyte size was calculated as in Fig.
6D. Data are means  SEM of 5–30 animals per group. *P < 0.01. (A high-quality color representation of this ﬁgure is available in the online
issue.)
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(46). Therefore, it is possible that part of the insulin
hypersensitivity detected in GRK2
/ mice and the protec-
tion afforded to the development of insulin-resistant con-
ditions in these animals could be related to the observed
changes in adiposity. Future experiments involving tissue-
speciﬁc downregulation will provide new insight into the
understanding of the role of GRK2 in obesity and insulin
resistance.
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